HOSPIRA, INC. for HOSPIRA INC
A later version of this report replaces this one, so LegiList's totals use the current version instead. This page shows this version exactly as filed.
Versions of this report
Every filing the register holds for this firm, client and period, oldest first. The most recent one is the version LegiList counts.
| Filing | Filed | Amount | Counted |
|---|---|---|---|
| 1st Quarter - Report (this page) | Apr 20, 2015 | $390,000 | Replaced |
| 1st Quarter - Amendment | Jan 20, 2016 | $380,000 | Yes |
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Implementation of the Biologics Price Competition and Innovation Act (BPCIA)
| Lobbyist | Covered position, as disclosed |
|---|---|
| JULIANA REED | — |
| WENDY SUSSMAN | — |
Medicare/Medicaid MMM
Working to ensure that issues related to coding and reimbursement are discussed and addressed to ensure a smooth start to the coverage of biosimilar medications as they enter into the United States' prescription drug market this year.
| Lobbyist | Covered position, as disclosed |
|---|---|
| JULIANA REED | — |
| WENDY SUSSMAN | — |
Pharmacy PHA
Issues related to the naming of biosimilars as they enter into the national prescription drug marketplace; Supplemental Applications Proposing Labeling Changes for Approved Drugs and Biological Products Proposed Rule by FDA (RIN:0910-AG94)
| Lobbyist | Covered position, as disclosed |
|---|---|
| JULIANA REED | — |
| WENDY SUSSMAN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.